VTAK Stock Draws Traders As Flyte Bets Big On Volato

Catheter Precision Inc. stocks have been trading up by 27.63 percent amid highly positive sentiment from the most impactful headline

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading VTAK

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Flyte, the aviation arm of Catheter Precision (VTAK), led a financing in Volato, buying about 2.9 million shares for a 7.5% stake and becoming its largest shareholder.
A $2.2M strategic PIPE into Volato backs AI-enabled private aviation and regional air mobility tied to VTAK’s Flyte platform.
VTAK shares jumped nearly 3% on the Volato financing news, signaling trader interest in the new aviation strategy.
Flyte also teamed with GSE Worldwide and PGA TOUR golfer Emiliano Grillo to promote its Cirrus Vision Jet-based short-haul service at the 2026 U.S. Open.

Live Update At 10:02:36 EDT: On Tuesday, June 23, 2026 Catheter Precision Inc. stock [NYSE American: VTAK] is trending up by 27.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

VTAK is trading like a classic low-priced momentum name with heavy story risk. Over the past few weeks, Catheter Precision’s stock has bounced between roughly $0.82 and $1.16, closing near $1.11 on 2026/06/23. That puts VTAK up from late May levels around $0.88, but still chopping in a tight, volatile range.

The intraday tape shows classic day-trader action. On the most recent session, VTAK spiked premarket toward $1.55 before fading back near $1.10–$1.15. That kind of wick tells traders there’s hot money chasing headlines — and just as quickly taking profits.

Under the hood, Catheter Precision is still a heavy cash-burn story. Quarterly revenue was only $432,000, but operating expenses ran about $2.71M, producing an operating loss near $2.32M and net loss around $1.68M. Free cash flow was about -$2.80M for the quarter. The balance sheet shows just $441,000 in cash against current liabilities of roughly $19.7M and a current ratio of 0.1 — very tight.

More Breaking News

For traders, that means VTAK’s chart is driven far more by news and speculation than by near-term profits. Any fresh catalyst — like the Flyte and Volato moves — can spark sharp swings in either direction.

Why Traders Are Watching VTAK’s Flyte–Volato Bet

The story pulling traders into VTAK right now is not its legacy medical technology. It is Flyte, Catheter Precision’s aviation-focused subsidiary, and its aggressive push into AI-enabled private aviation and regional air mobility.

Through Flyte, Catheter Precision led a broader financing round for Volato, a private aviation operator, and scooped up about 2.9M Volato shares. That translates to a 7.5% stake and makes Flyte Volato’s largest shareholder. This is not a token position. It gives VTAK a real voice in how Volato’s platform evolves.

On top of that, Catheter Precision also led a $2.2M strategic PIPE into Volato Group. Management’s stated aim is to build collaboration across the private aviation ecosystem, using AI and shared infrastructure to connect Flyte’s regional mobility platform with Volato’s fleet and customer base. The market liked the ambition: VTAK shares popped nearly 3% on the financing news.

For active traders, this is exactly the kind of narrative shift that can fuel multi-day moves. VTAK is trying to rebrand a portion of its story as an AI-plus-aviation play, a theme that has drawn strong interest in other small caps. The risk is clear — Catheter Precision is layering a new, capital-intensive business on top of an already loss-making core. But the upside, if Flyte and Volato execute, is a much larger potential market than its original niche.

Flyte’s marketing deal with GSE Worldwide and PGA TOUR pro Emiliano Grillo reinforces that ambition. Debuting the partnership at the 2026 U.S. Open, Flyte is positioning its Cirrus Vision Jet-based short-haul service directly in front of high-net-worth athletes and the sports-business ecosystem. For VTAK traders, that signals a go-for-growth strategy rather than a slow, cautious rollout.

Conclusion

VTAK is evolving into a hybrid story: a small, loss-making company with a stretched balance sheet, but a bold aviation and AI narrative through Flyte and the Volato stake. The numbers show Catheter Precision burning cash, sporting negative margins, and relying on external financing to fund operations and new ventures. That is classic high-risk small-cap territory.

At the same time, the Flyte–Volato moves are exactly the kind of catalysts momentum traders hunt. A 7.5% position and largest-shareholder status in Volato, plus a $2.2M PIPE and a high-visibility sports marketing push, give headline writers plenty to work with. Recent intraday spikes toward the mid-$1s show how quickly VTAK can move when that story catches fire.

For disciplined traders, the setup is straightforward: treat VTAK as a speculative, news-driven ticker where risk management matters more than the dream. The balance sheet and cash flow numbers demand respect. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful gamblers.” In the same spirit of focusing on price action and discipline, this is where Tim Bohen’s approach also resonates; as Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. Anyone trading VTAK needs a plan, clear levels, and the willingness to cut losses fast if the Flyte narrative stalls.

This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!